Gerontology and Nutrition

Abstract

Alzheimer’s disease (AD) is a severe neurological illness affecting millions worldwide. The disease causes gradual memory loss, mental deterioration, and changes in behavior that eventually lead to a loss of autonomy and a worse quality of life. Due to demographic shifts and other lifestyle influences, the incidence of AD is forecast to skyrocket over the next several decades. This essay gives a synopsis of Alzheimer’s disease, including its epidemiology, risk factors, diagnosis, therapy, and preventative options.

According to current data, around 50 million individuals worldwide are living with dementia, with Alzheimer’s disease being the most frequent kind. It is predicted that by 2050, 13.8 million Americans will be living with AD, up from the current estimate of 6.2 million. The worldwide cost of dementia care is projected to exceed $1.1 trillion by 2030, illustrating the enormous economic burden of AD.

Effective Alzheimer’s disease treatment and preventive measures are desperately required. Indeed, there are not any therapies that can slow or stop the progression of AD, but there are a number of drugs that can assist with the symptoms. Research into novel medicines, such as immunotherapies and gene therapies, continues. Some evidence suggests that the chance of acquiring AD may be lowered by using preventative measures such as regular exercise, a balanced diet, and mental stimulation.

In summary, AD is a serious public health problem that will have far-reaching consequences for people, communities, and nations throughout the globe. In order to lessen the blow of this dreadful illness, it is essential that we do all in our power to raise public understanding, enhance medical diagnostics, and provide potent therapies and preventative measures.

Introduction

Alzheimer’s disease (AD) is a gradual and irreversible neurological ailment that destroys brain cells, causing cognitive decline, memory loss, and behavioral abnormalities. Alzheimer’s disease now affects around 5.8 million Americans, with the condition affecting 30-50% of seniors over the age of 85. (Gaugler et al., 2022). For those who are 65 years or older, the number of new cases will double every five years. As a result, the number of people dealing with AD is projected to grow rapidly over the next several decades. This research paper will cover a wide range of topics linked to Alzheimer’s disease (AD), including its etiology, diagnosis, therapy, nutritional implications, preventative ideas, present statistics, and projected expenditures.

Current and Future Statistics and Costs

Alzheimer’s disease (AD) is a chronic neurological illness that causes memory loss, poor thinking, and personality changes in the brain. The Alzheimer’s Association estimates that 6.2 million Americans aged 65 and older will have Alzheimer’s dementia by 2021. (Gaugler et al., 2022). Furthermore, younger-onset Alzheimer’s affects around 200,000 People under the age of 65. According to current projections, 13.8 million Americans will have Alzheimer’s dementia by 2050, with a new case being diagnosed every 33 seconds (Gaugler et al., 2022). The illness is most common in low- and middle-income nations, where the population is becoming older and hence more susceptible.

The expenses of Alzheimer’s disease are tremendous. The Alzheimer’s Society estimates that by 2021, the overall cost of providing care for people with Alzheimer’s disease and other dementias in the United States will be $355 billion, with Medicare and Medicaid paying for $239 billion of that (Gaugler et al., 2022). It is estimated that by 2050, the price will have risen to about $1.1 trillion. It is obvious that people, families, and government programs will all chip in, but that people’s loved ones and unpaid carers will shoulder the lion’s share.

Thus, more funding for Alzheimer’s research is required to meet the rising public health issue of the disease. Governments must also examine methods to help families and caregivers, who often offer substantial and expensive care to Alzheimer’s patients.

Pathophysiology and Impact on the Body

The pathogenesis of Alzheimer’s disease is defined by the formation of aberrant protein aggregates, such as beta-amyloid plaques and tau protein tangles, in the brain (Mayo Clinic, 2021). These protein aggregates cause neuronal injury and death, resulting in cognitive decline and memory loss. Moreover, Alzheimer’s disease (AD) primarily affects the areas of the brain called the hippocampus and prefrontal cortex (Mayo Clinic, 2021).

The illness typically affects the brain and nerve system but may also have far-reaching effects elsewhere in the body. For instance, the autonomic nervous system may be impacted, resulting in modifications to the control of body temperature and blood pressure. Furthermore, the immune system may be weakened, making the individual more susceptible to infections and other illnesses.

Alzheimer’s disease symptoms vary from person to person, but they often include memory loss, confusion, trouble speaking, mood or behavior changes, and loss of independence. Patients may have difficulties with everyday tasks such as dressing, washing, and eating as the condition develops. As time passes, they may become bedridden and need constant attention (WHO, 2023).

Differences between Early Onset and Late-Onset Alzheimer’s Disease

In the context of Alzheimer’s disease, the beginning of symptoms before age 65 is considered early onset. It only accounts for 5-10% of all instances of Alzheimer’s disease, making it very uncommon (Mayo Clinic, 2021). Researchers have linked mutations in three genes (APP, PSEN1, and PSEN2) to the development of Alzheimer’s disease at an early age.

In contrast, Alzheimer’s disease with a late start, defined as the development of symptoms beyond the age of 65, is very frequent. It is thought to be caused by a mix of genetic, environmental, and lifestyle factors. Risk factors for late-onset Alzheimer’s disease include age, a family history of the disease, a head injury, high blood pressure, high cholesterol, and diabetes (Galvin et al., 2021).

Compared to late-onset Alzheimer’s disease, early-onset Alzheimer’s disease is characterized by more rapid symptom progression and a more severe effect on the patient’s quality of life. While the drugs used and the treatment of symptoms are similar for both early and late-onset Alzheimer’s disease, there are several key variances (Galvin et al., 2021).

Lifestyle

Genetic susceptibility to EOAD and a history of dementia in the family may both play a role in the development of the disorder. They may also be more likely to have an active lifestyle, with things like regular full-time employment and more social interaction (Parnetti et al., 2019).

Physical Differences

Those suffering from EOAD may potentially have brain damage in several areas. Those with early-onset Alzheimer’s disease (EOAD) may, for instance, have more generalized brain shrinkage than those with late-onset AD (Galvin et al., 2021). In addition, they may have additional visual-spatial deficits, including impaired depth perception and linguistic difficulties.

Diagnosis

Diagnosis of EOAD may be difficult since it is often misinterpreted as sadness, worry, or stress owing to the individual’s younger age. The illness was formerly difficult to diagnose in its early stages, but recent developments in neuroimaging methods have changed that. For instance, PET scans may identify a beta-amyloid protein, a sign of Alzheimer’s disease, in the brain (Parnetti et al., 2019).

Treatment

While cholinesterase inhibitors and memantine are recommended to treat the disease’s symptoms, a cure for Alzheimer’s disease has yet to be found. However, studies have indicated that those with EOAD may not react to these treatments as well as those with late-onset AD (Galvin et al., 2021). Those with EOAD may also benefit more from behavioral therapies like cognitive stimulation therapy and physical activity.

In conclusion, EOAD varies from late-onset Alzheimer’s disease in terms of lifestyle, physical changes, diagnosis, and therapy. In order to treat and assist people with EOAD effectively, healthcare providers must be aware of these distinctions.

Diagnosis of Alzheimer’s Disease and New Research

Currently, a diagnosis of AD calls for a comprehensive medical examination in addition to cognitive tests. To rule out other illnesses that may produce similar symptoms, the examination involves a thorough medical history, neurological and physical exams, and testing, including blood tests and brain imaging. Cognitive testing evaluates memory, linguistic skills, problem-solving ability, attention, and other cognitive processes (Montoliu-Gaya et al., 2021).

The National Institute on Aging has also published diagnostic guidelines for identifying the disease. These guidelines involve a two-part process: the first step is to confirm the existence of dementia, and the second step is to confirm the existence of AD as dementia’s primary cause (National Institute on Aging, 2021).

New research has recently concentrated on finding biomarkers for the early identification and diagnosis of Alzheimer’s disease. Biomarkers are compounds that may be measured in the body to detect the presence of illness (Montoliu-Gaya et al., 2021). In the case of Alzheimer’s disease, researchers are investigating the use of biomarkers in the cerebrospinal fluid, such as beta-amyloid and tau protein, as well as changes in brain structure and function detectable by imaging methods such as positron emission tomography (PET) and magnetic resonance imaging (MRI) (Montoliu-Gaya et al., 2021).

One potential technique for AD diagnosis is using machine learning algorithms to assess massive clinical and imaging data datasets. For instance, recent research successfully predicted who among over 1,100 people with brain MRI data will acquire AD over the following five years using machine learning algorithms (Montoliu-Gaya et al., 2021).

Researchers are also investigating using artificial intelligence and machine learning algorithms to increase the efficacy and accuracy of AD diagnosis and create new diagnostic tools (National Institute on Aging, 2021). The potential for these methods to provide earlier and more accurate diagnoses of AD is promising for their potential to enhance treatment results and patient and family well-being.

Current Treatments and New Research

While there is currently no known cure for Alzheimer’s disease, the Food and Drug Administration (FDA) has authorized several effective treatments. Both cholinesterase inhibitors (ChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists are used to treat Alzheimer’s disease. NMDA receptor antagonists control the action of glutamate, an excitatory neurotransmitter that has been linked to a cognitive loss in Alzheimer’s disease, whereas cholinesterase inhibitors (ChEIs) block the breakdown of acetylcholine, a neurotransmitter crucial for memory and learning (Ozben & Ozben, 2019).

The three ChEIs presently authorized by the FDA for treating Alzheimer’s disease are donepezil, rivastigmine, and galantamine. While these medications have been demonstrated to enhance AD patients’ cognitive performance and ADLs, they are not without their share of adverse effects, including nausea, vomiting, and diarrhoea (Ozben & Ozben, 2019). In addition to ChEIs, the NMDA receptor antagonist memantine has been licensed by the FDA for the treatment of AD. When compared to ChEIs, memantine’s adverse effects are milder, with headache and dizziness being the most prevalent (Ozben & Ozben, 2019).

In addition to the FDA-approved treatments, numerous more medications are being studied for their possible use in treating AD. In clinical trials, for example, medications targeting beta-amyloid, a protein that accumulates in the brains of Alzheimer’s sufferers and forms plaques, are being explored (Ozben & Ozben, 2019). Drugs that inhibit the aberrant aggregation of tau protein, which contributes to the formation of neurofibrillary tangles in the brains of people with AD, are another strategy (Nguyen et al., 2021).

Moreover, non-pharmacological therapies such as cognitive training, physical activity, and diet modification have shown promise in the treatment of Alzheimer’s disease. Cognitive training may enhance cognitive performance and prevent cognitive decline in people with Alzheimer’s disease, according to a comprehensive review and meta-analysis of randomized controlled studies (Zhou et al., 2022). The cognitive abilities and brain structure of Alzheimer’s disease patients have been proven to improve with regular physical activity, particularly aerobic exercise (Dhir et al., 2021). The consumption of a diet more typical of the Mediterranean region, one rich in fresh produce, whole grains, and healthy fats, has been linked to a decreased risk of dementia and Alzheimer’s disease (McGrattan et al., 2019).

Generally, although there is no known cure for AD, patients’ cognitive performance and quality of life may be improved by FDA-approved medications and non-pharmacological therapies. In order to better understand and treat this crippling condition, ongoing research is looking at novel diagnostic techniques and therapy approaches.

Nutrition-related considerations for an AD patient

For effective Alzheimer’s disease treatment, proper diet is crucial (AD). A healthy diet should consist mostly of plant foods, whole grains, lean proteins, and healthy fats (McGrattan et al., 2019). Certain adjustments, however, are necessary to provide proper nutrition and avoid difficulties for AD patients.

Patients with Alzheimer’s may struggle with losing weight for various reasons, including a lack of appetite, difficulties swallowing, and increased activity levels. For this reason, it is crucial to provide tasty, calorie-rich foods that are also simple to digest. It is common advice to eat foods that are soft or pureed, drink liquids that have been thickened and eat frequent, little meals (McGrattan et al., 2019).

According to Agnihotri and Aruoma (2020), high consumption of fruits, vegetables, and whole grains may help reduce the chance of getting AD. A low-saturated fat, low-cholesterol, and low-trans-fat diet are also advised. The Mediterranean diet, which is heavy in plant-based foods, seafood, nuts, and healthy fats, has also been linked to a lower incidence of Alzheimer’s disease.

One-Day Diet Plan for an 80 Y/O AD Patient:

The patient’s capacity to eat may be affected not only by the kind of food offered but also by how the food is presented. Individuals with Alzheimer’s disease may have trouble distinguishing various foods due to visual-spatial issues. As a result, meals should be presented aesthetically appealingly, with contrasting colors and textures. In addition, the patient’s ability to concentrate on eating may be enhanced by utilizing colored plates and cups and eliminating distractions like loud sounds or television during meals (McGrattan et al., 2019).

Lastly, it is important for carers to remember to stay hydrated. Dehydration may cause disorientation and other problems. Thus, it is important for caregivers to make sure patients have constant access to fluids such as water. Increasing fluid intake may also be accomplished by blending water-rich fruits and vegetables, such as melons and cucumbers (McGrattan et al., 2019).

Prevention theories: Exercise, Diet, Lifestyle Changes

Alzheimer’s disease (AD) preventative strategies focus on modifying factors, including nutrition, physical activity, and stress levels. Exercise has been shown to lower the risk of developing AD by boosting cerebral blood flow and enhancing cognitive performance. According to Livingston et al. (2020), living a healthy lifestyle that includes regular exercise, a balanced diet, and stress reduction may lower the chance of acquiring AD by up to 60%.

The cognitive advantages and lower risk of AD have been linked to the consumption of a Mediterranean diet rich in fruits, vegetables, nuts, legumes, whole grains, and seafood (Scarmeas et al., 2006). Another factor associated with a reduced risk of AD is a diet low in saturated and trans fats (Yuan et al., 2021). The function of nutrition in preventing AD has been studied, but the data still needs to be definitive; further study is required.

Changes in lifestyle, such as participating in intellectually stimulating hobbies and social contacts, have also been related to a lower incidence of Alzheimer’s disease (Ballarin et al., 2021). Other ways to lessen the likelihood of developing AD include giving up cigarettes and reducing alcohol use (Livingston et al., 2020).

Preventing Alzheimer’s disease is complex, including a wide range of measures. Potential risk factors for Alzheimer’s disease (AD) may be modified via lifestyle choices such as regular exercise, a good diet, stress management, and mental stimulation. Nevertheless, further study is required to determine whether or not these preventative hypotheses are helpful.

Conclusion

Alzheimer’s disease is a severe illness that affects millions of people globally. It is crucial to learn about the biology of the illness, its effects on the body, and the available therapies and preventative measures as the number of reported cases rises steadily. Several studies have shown a link between healthy lifestyle choices, including regular exercise, a nutritious diet, and meaningful social interactions with a lower chance of acquiring Alzheimer’s disease. Moreover, giving AD patients balanced and nutritious food, as well as eating assistance, may aid in the maintenance of their general health and well-being.

References

Gaugler, J., James, B., Johnson, T., Reimer, J., Solis, M., Weuve, J., … & Hohman, T. J. (2022). 2022 Alzheimer’s disease facts and figures. ALZHEIMERS & DEMENTIA, 18(4), 700-789.

Mayo Clinic. (2021). Alzheimer’s disease. Retrieved from https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447

World Health Organization: WHO. (2023). Dementia. Retrieved from https://www.who.int/news-room/fact-sheets/detail/dementia

Parnetti, L., Chipi, E., Salvadori, N., D’Andrea, K., & Eusebi, P. (2019). Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis. Alzheimer’s research & therapy, 11, 1-13.

Galvin, J. E., Aisen, P., Langbaum, J. B., Rodriguez, E., Sabbagh, M., Stefanacci, R., … & Rubino, I. (2021). Early stages of Alzheimer’s disease: evolving the care team for optimal patient management. Frontiers in Neurology, 11, 592302.

National Institute on Aging. (2021, February 17). Alzheimer’s disease and related dementias: Research advances and challenges. Retrieved from https://www.nia.nih.gov/health/alzheimers

Montoliu-Gaya, L., Strydom, A., Blennow, K., Zetterberg, H., & Ashton, N. J. (2021). Blood biomarkers for Alzheimer’s disease in Down syndrome. Journal of Clinical Medicine, 10(16), 3639.

McGrattan, A. M., McGuinness, B., McKinley, M. C., Kee, F., Passmore, P., Woodside, J. V., & McEvoy, C. T. (2019). Diet and inflammation in cognitive ageing and Alzheimer’s disease. Current nutrition reports, 8, 53-65.

Ozben, T., & Ozben, S. (2019). Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease. Clinical biochemistry, 72, 87-89.

Dhir, S., Teo, W. P., Chamberlain, S. R., Tyler, K., Yücel, M., & Segrave, R. A. (2021). The effects of combined physical and cognitive training on inhibitory control: a systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 128, 735-748.

Zhou, S., Chen, S., Liu, X., Zhang, Y., Zhao, M., & Li, W. (2022). Physical activity improves cognition and activities of daily living in adults with alzheimer’s disease: A systematic review and meta-analysis of randomized controlled trials. International Journal of Environmental Research and Public Health, 19(3), 1216.

Nguyen, T. T., Nguyen, T. T. D., Nguyen, T. K. O., & Vo, T. K. (2021). Advances in developing therapeutic strategies for Alzheimer’s disease. Biomedicine & Pharmacotherapy, 139, 111623.

Agnihotri, A., & Aruoma, O. I. (2020). Alzheimer’s disease and Parkinson’s disease: a nutritional toxicology perspective of the impact of oxidative stress, mitochondrial dysfunction, nutrigenomics and environmental chemicals. Journal of the American College of Nutrition, 39(1), 16-27.

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., … & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. The Lancet, 396(10248), 413-446.

Yuan, C., Chen, H., Wang, Y., Schneider, J. A., Willett, W. C., & Morris, M. C. (2021). Dietary carotenoids related to risk of incident Alzheimer dementia (AD) and brain AD neuropathology: a community-based cohort of older adults. The American journal of clinical nutrition, 113(1), 200-208.

Ballarini, T., van Lent, D. M., Brunner, J., Schröder, A., Wolfsgruber, S., Altenstein, S., … & DELCODE Study Group. (2021). Mediterranean diet, Alzheimer disease biomarkers, and brain atrophy in old age. Neurology, 96(24), e2920-e2932.